Qube Research & Technologies (QRT)
CYT

Qube Research & Technologies (QRT)’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-4
Closed -$12 – 4993
2023
Q4 		$12 Hold
4
– – ﹤0.01% 4161
2023
Q3 		$11 Buy
+4
New +$11 ﹤0.01% 3922
2022
Q4 		– Sell
-11,796
Closed -$23K – 3127
2022
Q3 		$23K Buy
11,796
+522
+5% +$1.36K ﹤0.01% 2278
2022
Q2 		$34K Buy
+11,274
New +$28.8K ﹤0.01% 2193
2021
Q3 		– Sell
-16,168
Closed -$346K – 2918
2021
Q2 		$346K Buy
+16,168
New +$303K ﹤0.01% 1491

Other funds holding CYT

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BFO
Boston Family Office Boston, Massachusetts $1.5B AUM 11.68% 1-Year Est. Return
LC
Lindbrook Capital Calabasas, California $1.08B AUM 10.14% 1-Year Est. Return

Qube Research & Technologies (QRT)'s CYT Position: Q1 2024 in Review

Qube Research & Technologies (QRT) sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q1 2024, closing a stake of 4 shares — an estimated $12 sold.

Qube Research & Technologies (QRT) first reported a position in CYT in Q2 2021 and held it in 5 quarters. The position peaked at $346K in Q2 2021. 4 funds tracked by Wall St. Rank hold CYT as of Q1 2024.

  • Qube Research & Technologies (QRT) reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 4 Cyteir Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $12.
  • Qube Research & Technologies (QRT) first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
  • Qube Research & Technologies (QRT)'s Cyteir Therapeutics, Inc. Common Stock position peaked at $346K in Q2 2021.
  • 4 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q1 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2024, filed 14 May 2024.